that's all i heard so far
25% increase to total shares, almost 50% increase to float.
Adds $30MM, to $200MM which for a clinical biotech seems undervalued still. Should be at $12 or higher, just based on the Alny deal with pending $5MM milestone coming in Dec for iniating TTR P3.
Sentiment: Strong Buy